相关临床试验
17
16 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
1961
进行中（未招募）
16
94.1%
已完成
1
5.9%
暂无批准数据
- The LORD trial of 1,423 patients with low-risk ductal carcinoma in situ (DCIS) found that active surveillance resulted in comparable early outcomes to immediate surgery, with 6% developing invasive cancer versus 9% in the surgery group. - Researchers presented reassuring interim results at the 15th European Breast Cancer Conference, showing that tumors detected during active surveillance were only slightly larger but not more aggressive than those found with immediate treatment. - The study contributes important evidence for reducing overtreatment in breast cancer care, as research suggests four out of five DCIS cases never become invasive or life-threatening. - Longer follow-up will be crucial before clinical guidelines can be changed, but early findings support the potential for a more de-escalated approach to managing selected low-risk DCIS patients.
- myTomorrows announced its first large-scale partnership in Spain with Clínica Universidad de Navarra to implement AI-assisted patient-trial matching technology integrated within the hospital's electronic health record system. - The AI system leverages large language models to analyze clinical variables and cross-check patient information against eligibility criteria across CUN's portfolio of more than 200 active clinical trials. - The collaboration introduces a phased deployment model that enables clinicians to access structured lists of potentially eligible trials directly within patient records during routine clinical workflows. - A CUN-branded referral platform will allow external physicians to AI-pre-screen patients and submit referrals with real-time visibility into trial availability and cohort status.
- The combination of teclistamab and daratumumab demonstrated overall response rates ranging from 70% to 100% across different doses in heavily pretreated multiple myeloma patients with a median of 5 prior lines of therapy. - A high proportion of patients achieved deep responses including very good partial responses or better, with responses occurring quickly in the first month and deepening over time. - The combination was well-tolerated with no new adverse effects compared to the safety profiles of the individual drugs, supporting its evaluation in the ongoing phase 3 MajesTEC-3 study. - Comparative effectiveness data from MajesTEC-1 showed teclistamab significantly improved progression-free survival compared to real-world treatments in triple-class exposed patients.
